سلوفاكيا - السلوفاكية - myHealthbox

bayer ag - dispergovateľné granule - iprovalicarb 40 g/kg; folpet 250 g/kg; fosetyl-al 500 g/kg

سلوفاكيا - السلوفاكية - myHealthbox

bayer ag - suspenzný koncentrát - spirotetramat 100 g/l

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - imunitný séra a imunoglobulíny, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanóm - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - imunitný séra a imunoglobulíny, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidové zobrazovanie - diagnostické rádiofarmaká - tento liek je určený len na diagnostické účely. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatic neoplasms, kastrácia-odolný - terapeutické rádiofarmaká - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

سلوفاكيا - السلوفاكية - myHealthbox

bayer ag - suspenzný koncetrát - aclonifen 600 g/l

سلوفاكيا - السلوفاكية - myHealthbox

bayer ag - dispergovateľné granule - iprovalicarb 40 g/kg; folpet 250 g/kg; fosetyl-al 500 g/kg